STTK advances DR3 blockade for IBD; induction data slated for H1 2028
STTK is advancing DR3 blockade as a differentiated IBD approach, targeting superior maintenance efficacy and lower immunogenicity versus TL1A and IL-23 therapies. Induction data are expected in H1 2028 as trials continue.
The company is advancing DR3 blockade as a differentiated approach in IBD, with the aim of delivering stronger maintenance efficacy and lower immunogenicity than TL1A and IL-23 therapies. Key trials are underway, and induction data are expected in H1 2028, while a strong cash position supports ongoing and future…